Skip to main content

Table 6 Multivariate analyses (cox regression) of overall survival a in younger and older patients

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Variables

Patients ≦ 60 y/o

Patients > 60 y/o

 

95% CI

  

95% CI

 

HR

Lower

Upper

P

HR

Lower

Upper

P

NPM1 b

0.000

0.000

1.490E89

0.898

0.263

0.021

3.377

0.305

FLT3- ITDc

7.505

1.538

36.614

0.013*

3.235

0.424

24.699

0.258

FLT3- TKD

9765.104

32.249

2.95E6

0.002*

144.617

0.000

3.75E169

0.980

CEBPA d

0.357

0.125

1.020

0.054

1.090

0.292

4.066

0.898

IDH1 b

14220.871

0.000

3.9E99

0.932

174.990

0.000

4.56E169

0.979

IDH2 b

0.000

0.000

2.695E210

0.958

0.459

0.050

4.242

0.492

DNMT3A b

146.313

0.000

4.16E97

0.965

    

MLL b

0.059

0.000

1.78E94

0.980

2.245

0.173

29.122

0.536

MN1 e

1.923

1.130

3.273

0.016*

1.198

0.916

1.567

0.187

ERG

53.777

1.820

1589.377

0.021*

32.349

2.889

362.237

0.005*

miR-181a

0.514

0.260

1.014

0.055

1.361

0.933

1.986

0.110

miR-3151

1.164

0.580

2.337

0.669

0.423

0.191

0.935

0.033*

BDH2 e

4.829

1.002

23.274

0.050*

18.937

1.571

228.308

0.021*

  1. Abbreviations: HR indicates Hazard ratio; CI, confidence interval.
  2. aOnly patients with intensive induction chemotherapy enrolled.
  3. bNPM1mut versus NPM1wild type; ID H1mut versus IDH1wild type; IDH2mut versus IDH2wild type; DNMT3Amut versus DNMT3Awild type.
  4. cFLT3- ITDmut versus FLT3- ITDneg.
  5. dCEBPAdouble-mutation versus CEBPAsingle mutation versus CEBPAno mutation.
  6. eBDH2high relative to BDH2low group.
  7. *Statistically significant (P < 0.05).